Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapid Biktarvy initiation in treatment-naive adults with advanced HIV disease
2019-003614-14Phase 4Completed
- Sponsor
- National Institute for Infectious Diseases Lazzaro Spallanzani
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by National Institute for Infectious Diseases Lazzaro Spallanzani. Primary endpoint: Time-to-clinical or virologic failure. Started Oct 2020; status: completed.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2019-003614-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003614-14.